Home 2023

Vertex Pharmaceuticals

StockWatch: For Genome Editing, Inflection Points Crowd the Calendar
GEN Edge

StockWatch: For Genome Editing, Inflection Points Crowd the Calendar

Alex Philippidis -
0
Meeting on the Mesa: How to Bring Cell and Gene Therapies to Market
Bioprocessing

Meeting on the Mesa: How to Bring Cell and Gene Therapies to Market

Jonathan D Grinstein, PhD -
0
StockWatch: Investors Shrug as FDA Weighs First Gene-Edited Therapy
Drug Discovery

StockWatch: Investors Shrug as FDA Weighs First Gene-Edited Therapy

Alex Philippidis -
437
Door Busters: Entrada Therapeutics Is Engaging Inaccessible Intracellular Targets
Drug Discovery

Door Busters: Entrada Therapeutics Is Engaging Inaccessible Intracellular Targets

Jonathan D Grinstein, PhD -
20
A16z’s Vijay Pande: Why Gene Editing Will Soon Be “Off to the Races”
Artificial Intelligence

A16z’s Vijay Pande: Why Gene Editing Will Soon Be “Off to the Races”

Alex Philippidis -
1
Arbor and Vertex to Advance Reverse Transcriptase Genetic Medicines
GEN Edge

Arbor and Vertex to Advance Reverse Transcriptase Genetic Medicines

Jonathan D Grinstein, PhD -
1
Manufacturing an Abundance of AAV Vectors
Bioprocessing

Manufacturing an Abundance of AAV Vectors

Kathy Vuksanaj -
0
Vertex Pays $900M Upfront to Lead CTX001 Development with CRISPR Therapeutics
Drug Discovery

Vertex Pays $900M Upfront to Lead CTX001 Development with CRISPR Therapeutics

Alex Philippidis -
0
CRISPR and Beyond: Advances in Gene Therapy
Featured

CRISPR and Beyond: Advances in Gene Therapy

Kevin Davies -
0
Vertex’s David Altshuler Humanizes Drug Discovery
Insights

Vertex’s David Altshuler Humanizes Drug Discovery

Julianna LeMieux, PhD -
0
123Page 1 of 3
Copyright © 2023 Genetic Engineering & Biotechnology News. All Rights Reserved.